SARS-COV-2 INHIBITORS

SARS-COV-2 INHIBITORS

Polypeptide inhibitors of SARS-CoV-2 are disclosed comprising an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17, 19-21, 23-34 an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CARTER, Lauren, WALLS, Alexandra, KOZODOY, Lisa, OGOHARA, Cassandra, VEESLER, David, BAKER, David, GORESHNIK, Inna, JEWETT, Michael, BOWEN, John, MILLER, Lauren, STEWART, Lance, WU, Kejia, DIAMOND, Michael, RAVICHANDRAN, Rashmi, CAO, Longxing, VOGELI, Bastian, COVENTRY, Brian, BOYKEN, Scott, CASE, James Brett, EDMAN, Natasha, HUNT, Andrew, PARK, Young-jun
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Polypeptide inhibitors of SARS-CoV-2 are disclosed comprising an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17, 19-21, 23-34 and 100-101, and their use for treating and limiting development of SARS-CoV-2 infection. L'invention concerne des inhibiteurs polypeptidiques du SARS-CoV-2 comprenant une séquence d'acides aminés au moins 50 %, 55 %, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 %, ou 100 % identique à la séquence d'acides aminés choisie dans le groupe constitué de SEQ ID NO : 1-17, 19-21, 23-34 et 100-101, et leur utilisation pour traiter et limiter le développement d'une infection par le SARS-CoV-2.